| Autor: |
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi, Shigeki Makino |
| Předmět: |
|
| Zdroj: |
Modern Rheumatology; 2018, Vol. 28 Issue 2, p227-234, 8p |
| Abstrakt: |
Objectives: In this study, iguratimod (IGU) was added to rheumatoid arthritis (RA) patients inadequately responding to 24-week or longer treatment with biological disease-modifying antirheumatic drug (bDMARDs), its effectiveness was assessed, and factors contributing to remission were evaluated. Methods: RA patients who fulfilled the following criteria were included: (i) ≤24-week of bDMARDs; (ii) 2.6
|
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
